Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy (AlloMem)

This study has been completed.
Sponsor:
Collaborator:
Proxy Biomedical Limited
Information provided by (Responsible Party):
Conor Delaney, MD, PhD, University Hospitals of Cleveland
ClinicalTrials.gov Identifier:
NCT01113736
First received: April 12, 2010
Last updated: June 16, 2014
Last verified: June 2014

April 12, 2010
June 16, 2014
January 2010
July 2012   (final data collection date for primary outcome measure)
If there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy. [ Time Frame: Average 1 hour during formation of ileostomy ] [ Designated as safety issue: Yes ]
Change in adhesion formation will be analyzed via the primary outcome of ileostomy mobilization time during ileostomy closure and the secondary outcome of an adhesion grading scale.
Determine if there is a decrease on adhesion formation of AlloMEM™ used in formation of a temporary loop ileostomy. [ Time Frame: 1 hour ] [ Designated as safety issue: Yes ]
Change in adhesion formation will be analyzed via the primary outcome of ileostomy mobilization time during ileostomy closure and the secondary outcome of an adhesion grading scale.
Complete list of historical versions of study NCT01113736 on ClinicalTrials.gov Archive Site
Decrease in operative time and a promotion of peritoneal remodeling [ Time Frame: During 3 month ileostomy closure ] [ Designated as safety issue: Yes ]
The objective of this study is therefore, to investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients. Benefit will be defined, for purposes of this study, as a decrease in adhesions resulting in decreased operative time during ileostomy closure, with promotion of peritoneal remodeling
Promotion of peritoneal remodeling in absent or traumatized native peritoneum [ Time Frame: During 3 month ileostomy closure ] [ Designated as safety issue: Yes ]
The objective of this study is therefore, to investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients. Benefit will be defined, for purposes of this study, as a decrease in adhesions resulting in decreased operative time during ileostomy closure, with promotion of peritoneal remodeling
Not Provided
Not Provided
 
Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy
Pilot Study Evaluating the Efficacy of AlloMEM in Prevention of Intraperitoneal Adhesions & Peritoneal Regeneration After Loop Ileostomy

The objective of this study is to investigate whether the use of Human Peritoneal Membrane (HPM) in a temporary loop ileostomy is beneficial to patients. Benefit will be defined, for purposes of this study, as a decrease in adhesions resulting in decreased operative time during ileostomy closure, with promotion of peritoneal remodeling.

A loop ileostomy is a common procedure used to divert fecal matter from anastomotic sites after abdominal surgeries. Major complications from creation and subsequent closure of a temporary loop ileostomy include: stoma retraction, stoma prolapsed, stenosis, herniation, intra-abdominal abscess, anastomotic leak, wound dehiscence. Small-bowel obstruction (SBO) was the most common complication. SBO is caused by adhesions in the surgical site, with narrowing or angulation of the intestine causing obstruction. Prevention of these adhesions may reduce the frequency with which SBO is seen after this surgery. Furthermore, surgery to close the ileostomy is complicated by the presence of adhesions which make dissection of the ileostomy difficult, and increase the risk of injury of the small intestine during dissection, prolonging the operation time in an effort to minimize risk to the patient.

AlloMEM™ is human peritoneal membrane designated by the Food and Drug Administration (FDA) for use as a homologous tissue where native peritoneum is absent or traumatized. The AlloMem™ is not regulated as a device and no 510k submission has been made by the FDA. AlloMem™ is allogeneic freeze-dried, irradiated human peritoneal membrane used as a soft tissue wound covering solely regulated under 361 HCT/P because by FDA definition it is: minimally manipulated; intended for homologous use only; does not involve the combination of cell or other tissues, and does not rely on the metabolic function of cells for its primary function. Two animal studies have shown that AlloMEM™ can help prevent intra-abdominal adhesions and provides the biological framework for peritoneal remodeling. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.

Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Colon Cancer
  • Rectal Cancer
Biological: AlloMEM™
To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
Other Name: Human Peritoneal Membrane
Experimental: Human Peritoneal Membrane
For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
Intervention: Biological: AlloMEM™

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Between 18 - 85 years old at the time of ileostomy formation
  • Scheduled to undergo planned diverting loop ileostomy

Exclusion Criteria:

  • Patients undergoing emergency surgery
  • Patients with abdominal or pelvic abscess present at time of initial surgery
  • Patients with a history of pulmonary embolism or deep vein thrombosis (DVT) within 1 year of surgery
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01113736
09-09-23, 09-09-23
Yes
Conor Delaney, MD, PhD, University Hospitals of Cleveland
Conor Delaney, MD, PhD
Proxy Biomedical Limited
Principal Investigator: Conor P. Delaney, MD, PhD University Hospital Case Medical Center
University Hospital Case Medical Center
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP